BioCentury | Oct 18, 2017
Translation in Brief

Neutrophil bias

...iron metabolism proteins, and in a rat model of stroke, the iron-binding and -transporting protein lactoferrin...
...like lactoferrin because they are safer than chelation, said Aronowski. His team is developing a lactoferrin-based...
BioCentury | Jul 15, 2013
Clinical News

PXL-01: Additional Phase II data

...Product: PXL-01 , PXL01 Business: Musculoskeletal Molecular target: NA Description: Synthetic peptide derived from human lactoferrin...
BioCentury | Dec 17, 2012
Clinical News

Talactoferrin: Phase III data

...AG (Xetra:AGX), Heidelberg, Germany Product: Talactoferrin Business: Cancer Molecular target: Dendritic cells Description: Recombinant human lactoferrin...
BioCentury | Dec 17, 2012
Clinical News

Talactoferrin: Final Phase I/II data

...AG (Xetra:AGX), Heidelberg, Germany Product: Talactoferrin Business: Infectious Molecular target: Dendritic cells Description: Recombinant human lactoferrin...
BioCentury | Dec 10, 2012
Company News

Ventria deal

...royalty-free rights in the U.S., France and Canada to undisclosed patents related to recombinant human lactoferrin...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...The company's next most advanced program is a topical formulation of talactoferrin, a recombinant human lactoferrin...
BioCentury | Sep 3, 2012
Company News

Agennix cancer news

...Phase III FORTIS-C trial of talactoferrin as first-line treatment for NSCLC. Talactoferrin, a recombinant human lactoferrin...
BioCentury | Aug 13, 2012
Clinical News

Talactoferrin: Phase III data

...AG (Xetra:AGX), Heidelberg, Germany Product: Talactoferrin Business: Cancer Molecular target: Dendritic cells Description: Recombinant human lactoferrin...
BioCentury | Aug 8, 2012
Clinical News

Agennix plummets on talactoferrin news

...non-small cell lung cancer. The news follows an announcement late Monday that the recombinant human lactoferrin...
BioCentury | Aug 7, 2012
Clinical News

Agennix's talactoferrin misses Phase III NSCLC endpoint

...28-day all-cause mortality compared to placebo plus standard of care. Talactoferrin is a recombinant human lactoferrin...
Items per page:
1 - 10 of 123